...
首页> 外文期刊>Journal of Analytical Toxicology >Comparison of Cocaine/Crack Biomarkers Concentrations in Oral Fluid, Urine and Plasma Simultaneously Collected From Drug Users
【24h】

Comparison of Cocaine/Crack Biomarkers Concentrations in Oral Fluid, Urine and Plasma Simultaneously Collected From Drug Users

机译:可卡因/裂纹生物标志物浓度在药物用户中同时收集的口服液,尿液和血浆中的浓度

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The use of oral fluid (OF) as an alternative specimen for drug analysis has become very popular in forensic toxicology. Many clinical studies have evaluated the correlations between concentrations of cocaine and its metabolites in OF and other matrices, but results have shown high variability. In addition, there are no data available regarding the correlations between biomarkers of crack-cocaine use in different matrices. This study evaluated the relationship between concentrations of cocaine/crack-cocaine biomarkers in OF, urine and plasma samples collected from cocaine users. All samples were analyzed for the presence of cocaine (COC), benzoylecgonine (BZE) and anhydroecgonine (AEC) by a validated liquid chromatography–mass spectrometry method. Median COC, BZE and AEC concentrations ranged from 4.20 to 33.26 ng/mL, from 13.03 to 3,615.86 ng/mL and from 7.40 to 1,892.5 ng/mL across matrices, respectively. The relationship between drug concentrations in OF versus plasma (OF/P) and OF versus urine (OF/U) was evaluated by their coefficients of determination (R2). Least-squares regression analyses demonstrated significant correlations between OF/P and OF/U for cocaine and BE (P 0.05), respectively. Many factors contribute to the variability of drug correlation ratios in studies involving random samples, including uncertainty about the time of last administration and dosage. Overall, we found significant R2 values for COC and BZE in OF/P and OF/U, but not for AEC. Despite the good correlations found in some cases, especially for BZE, the large variation in drug concentrations seen in this work suggests that OF concentrations should not be used to estimate concentrations of COC, BZE or AEC in plasma and/or urine.
机译:口服液(of)作为药物分析的替代样本在法医毒理学中已变得非常流行。许多临床研究已经评估了of和其他基质中可卡因及其代谢物浓度之间的相关性,但结果显示了很高的可变性。此外,没有关于不同基质中快克可卡因使用的生物标志物之间相关性的数据。本研究评估了从可卡因使用者身上采集的of、尿液和血浆样本中可卡因/快克可卡因生物标记物浓度之间的关系。采用经验证的液相色谱-质谱法分析所有样品中是否存在可卡因(COC)、苯甲酰降钙素(BZE)和脱水ecgonine(AEC)。基质中COC、BZE和AEC浓度中位数分别为4.20至33.26 ng/mL、13.03至3615.86 ng/mL和7.40至1892.5 ng/mL。通过测定系数(R2)评估OF与血浆(OF/P)和OF与尿液(OF/U)中药物浓度之间的关系。最小二乘回归分析显示可卡因和BE的OF/P和OF/U之间分别存在显著相关性(p0.05)。在涉及随机样本的研究中,许多因素导致药物相关性比率的可变性,包括最后一次给药时间和剂量的不确定性。总的来说,我们发现COC和BZE在OF/P和OF/U中有显著的R2值,但在AEC中没有。尽管在某些情况下发现了良好的相关性,尤其是BZE,但在这项研究中发现的药物浓度的巨大差异表明,不应使用OF浓度来估计血浆和/或尿液中COC、BZE或AEC的浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号